These preclinical results indicate that DNA damaging agents are effective and could be particularly useful in the treatment of PALB2-, BRCA1- or BRCA2- deficient pancreatic tumors, which is reminiscent of human cancers defective for ‘BRCAness’ [62, 63]. This evidence concerns the gene PALB2 and pancreatic neoplasm.